Prolonged viability of @entity1 skin xenografts in XXXX by @entity205 .

@entity1 @entity82 @entity137 @entity353 @entity5 @entity4483 @entity205 @entity35 @entity10002
The immunosuppressant @entity205 ( @entity10002 ) has shown usefulness in both animal and @entity1 transplantation. The present study investigated the effect of @entity10002 in @entity1 to @entity35 skin xenografts. Recipient @entity35 received either a fresh split-thickness (0.020 in.) or full-thickness graft obtained from plastic surgery, or frozen cadaver skin. The graft bed of recipient Lewis @entity35 was prepared by full-thickness excision. Animals were maintained on @entity10002 25 mg/kg/day X 50 days, followed by 12.5 mg/kg 2 X/week. Control animals received an equivalent volume of vehicle. All animals receiving split-thickness grafts and treated with @entity10002 maintained their grafts significantly longer (up to 255 days) than controls. The 2 @entity10002 -treated full-thickness grafts and the 10 vehicle-treated controls showed clinical and microscopic signs of rejection at a mean of 6.4 days. Histologic examination of successful grafts showed areas of viable epidermis with a negligible inflammatory infiltrate. There was some loss of normal polarity and occasional apoptotic pigmented basal cells. The dermis revealed moderate @entity82 , probably secondary to the surgical procedure. Graft viability was confirmed by autoradiography. Immunohistochemical staining for @entity4483 protein revealed morphologic alteration of suprabasilar dendritic (Langerhans-indeterminate) cells, as well as their existence in xenografts at 12 weeks posttransplantation. @entity137 reflected by @entity353 and blood chemistries were felt to be dose-dependent. This in vivo model may provide a means for testing percutaneous drug penetration and pharmacokinetics in @entity1 skin, and for observing the immune component of explanted cutaneous @entity5 and dermatoses.
